Drug Type Personalized antigen vaccine |
Synonyms- |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
ES-SCLC | Phase 2 | US | 30 Mar 2022 | |
ES-SCLC | Phase 2 | US | 30 Mar 2022 | |
Metastatic Renal Cell Carcinoma | Phase 2 | - | 31 Aug 2020 | |
Triple Negative Breast Cancer | Phase 1 | US | 23 Jul 2019 | |
Breast Cancer | Phase 1 | US | - | |
Prostatic Cancer | Phase 1 | US | - | |
Prostatic Cancer | Phase 1 | US | - |
Phase 1 | 18 | (Neoantigen DNA Vaccine + Durvalumab) | kzeobpodnl(oytxjkxbyu) = fxsdkioxim vqaijqdgmr (snfjriiulk, nxfauubwqo - ebwmsnmcwd) View more | - | 14 Dec 2023 | ||
TDS-IM system (Inchor Medical Systems)+Neoantigen DNA vaccine (Neoantigen DNA Vaccine) | kzeobpodnl(oytxjkxbyu) = uccpgybtxz vqaijqdgmr (snfjriiulk, viplczznjn - pcbmhxmkpn) View more | ||||||
Phase 1 | 15 | Peripheral blood draws+Personalized neoantigen DNA vaccine | hcxdrhuabn(cwtnixwrzj) = wnwtmuhilw gddmcwghwl (fjphjkdjlt, ojqbqjlpko - msgnzafwnq) View more | - | 04 Oct 2022 |